06185.HK
CanSino Biologics, Inc.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 25.78
−0.46%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.2B | 1.0B | 846.3M | 345.2M | 1.0B |
| Cost of Revenue | 424.1M | 350.2M | 244.4M | 1.2B | 1.2B |
| Gross Profit | 899.8M | 681.8M | 601.9M | (876.0M) | (186.6M) |
| Operating Expenses | |||||
| R&D Expense | 300.3M | 230.5M | 416.1M | 638.0M | 778.3M |
| SG&A Expense | 635.0M | 589.8M | 563.4M | 647.8M | 544.7M |
| General & Admin Expense | — | 173.1M | 194.4M | 294.5M | 278.1M |
| Selling & Marketing Expense | — | 416.7M | 369.1M | 353.4M | 266.6M |
| Other Expenses | 254.8M | (25.4M) | (20.7M) | (126.7M) | (140.8M) |
| Total Operating Expenses | 913.3M | 794.9M | 958.8M | 1.2B | 1.2B |
| Cost and Expenses | 1.3B | 1.1B | 1.2B | 2.4B | 2.4B |
| Operating Income (EBIT) | (51.5M) | (113.1M) | (375.2M) | (2.0B) | (1.4B) |
| Non-Operating | |||||
| Interest Income | 55.5M | 68.5M | 63.9M | 100.1M | 65.9M |
| Interest Expense | 18.1M | 55.8M | 60.0M | 64.1M | 41.3M |
| Net Interest Income | 37.3M | 12.7M | 3.9M | 35.7M | 24.1M |
| Other Non-Op Income/Expense | 87.7M | 134.3M | (6.0M) | 56.3M | 184.7M |
| Non-Operating Income (excl Interest) | — | — | 4.1M | (120.4M) | 318.3M |
| EBT (Pre-Tax Income) | 36.2M | 21.2M | (381.2M) | (2.0B) | (1.2B) |
| Income Tax Expense | 6.5M | (6.0M) | 2.5M | (11.5M) | (219.2M) |
| Bottom Line | |||||
| Net Income | 29.7M | 27.2M | (378.9M) | (1.5B) | (909.4M) |
| Earnings from Cont. Ops | 29.7M | 27.2M | (383.7M) | (2.0B) | (964.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 29.2M | 27.2M | (378.9M) | (1.5B) | (909.4M) |
| Per Share | |||||
| Basic EPS | HK$0.12 | HK$0.11 | (HK$1.53) | (HK$6.01) | (HK$3.68) |
| Diluted EPS | HK$0.12 | HK$0.11 | (HK$1.53) | (HK$6.01) | (HK$3.68) |
| Revenue Per Share | HK$5.06 | HK$4.07 | HK$3.42 | HK$1.40 | HK$4.17 |
| Shares | |||||
| Basic Shares Outstanding | 247.0M | 253.4M | 247.6M | 246.8M | 247.0M |
| Diluted Shares Outstanding | 247.0M | 253.4M | 247.6M | 246.8M | 247.0M |
| Profitability Metrics | |||||
| EBITDA | 43.4M | 61.0M | (163.8M) | (1.6B) | (1.3B) |
| D&A | 94.9M | 174.1M | 211.4M | 269.1M | 196.4M |
| EBIT | (51.5M) | (113.1M) | (375.2M) | (1.9B) | (1.5B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026